Onxeo Announces its Financial Agenda for 2021
Onxeo Announces its Financial Agenda for 2021
Paris (France), January 7, 2021 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) in oncology, in particular against rare or resistant cancers, today announced its financial agenda for 2021.
Event | Date* |
Full-year 2020 results | Tuesday, March 30, 2021 |
Shareholders’ general meeting | Wednesday, May 12, 2021 |
Half-year 2021 results | Wednesday, July 28, 2021 |
* This preliminary agenda may be modified. Press releases are published after financial markets close.